OCULOGICA Competitors

Synthego is a CRISPR solutions provider that enables the acceleration of life science research and development in the pursuit of improved human health. Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments. At Synthego, our values define who we are and how we work together to shape the future of science. Ingenuity drives us to innovate and solve complex challenges in groundbreaking ways. Collaboration fuels our success, as we believe the best ideas come from diverse perspectives working together. Kindness shapes our workplace culture, fostering mutual respect and care for one another. Empowerment inspires every team member to take initiative, grow, and make meaningful contributions. Integrity forms the foundation of everything we do, ensuring trust, transparency, and excellence guide our actions. We believe that fostering an environment of belonging is essential to driving innovation and collaboration. Through our Diversity Network Association (DNA), we actively amplify diverse voices, champion equity, and create spaces where inclusivity thrives. These principles are not just policies or initiatives; they’re integrated into our DNA and guide how we work together every day. By weaving diversity, equity, and inclusion into the fabric of our identity, we strengthen our team, inspire new ideas, and ensure everyone can contribute meaningfully to shaping the future of science.

CureMetrix is committed to the advancement of technology that improves disease detection and survival rates worldwide. Our AI-based products and research are focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, our powerful image analysis platform is an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their health. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs, and increased assurance that patients are getting the highest standard of care available from screening. Over the last 10 years since our founding in 2014, we have focused on building products with extremely high efficacy that are easy to install, operate within existing clinical workflows, and minimize extra steps from radiologists and patients. CureMetrix has partnered with practicing radiologists, cardiologists, and esteemed institutions around the world to collect over 5 million images to train and validate our algorithms. From breast cancer to heart disease to kidney disease we believe that AI can be used to improve outcomes for patients and extend the impact and value of screening programs globally.

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.